National Consortium for the Study of Terrorism and Responses to Terrorism

Volpara to showcase comprehensive product offerings at NCoBC 2023

Retrieved on: 
Thursday, March 23, 2023
Insurance, Pancreatic cancer, Professional services, Risk, US Foods, Partnership, PMID, Freedom, Health care, National Consortium for the Study of Terrorism and Responses to Terrorism, Heredity, Cancer, Data collection, Woman, ASX, Redondo Beach, California, Volpara, Breast, Radiology, Patient, Research, FDA, Mammography, Breast cancer, Software, Medical imaging, Nursing, Birth control, Mobile phone

LYNNWOOD, Wash., March 23, 2023 /PRNewswire/ -- Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection of cancer, is attending this year's National Consortium of Breast Centers (NCoBC) conference in Las Vegas to showcase its software advancements that are powering today's progressive breast centers.

Key Points: 
  • Volpara Thumbnail™ goes the extra mile to help patients understand their own breast density with image-enhanced results letters.
  • Volpara Risk Pathways™ provides a smooth workflow for healthcare providers assessing hereditary and lifetime breast cancer risk.
  • Volpara Hive™, the company's customer community, is expanding with a digital hub for networking with other users, sharing best practices, and providing product feedback.
  • To learn more about any of these product advancements, visit Volpara at NCoBC at booth #306 or request a virtual demo .

iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard

Retrieved on: 
Thursday, March 23, 2023
RMI, ICAD, II, Subjectivity, Food, National Consortium for the Study of Terrorism and Responses to Terrorism, Radiology, Woman, Breast, MBA, DBT, Risk, CMO, Associate, Organization, Hospital, Patient, Inc., Knowledge, Ageing, AI, Hospital Insurance and Diagnostic Services Act, FDA, Health, Regulation of tobacco by the U.S. Food and Drug Administration, Mammography, Conference, Breast cancer, Medical imaging

“We applaud the FDA for its recent decision to implement a national breast density reporting standard.

Key Points: 
  • “We applaud the FDA for its recent decision to implement a national breast density reporting standard.
  • The Company’s Breast AI Suite offers a 360-degree solution of clinically proven cancer detection, density assessment, and risk evaluation technologies, including PowerLook® Density Assessment, the world’s first multi-vendor deep-learning algorithm for standardizing breast density assessments using synthesized 2D images.
  • PowerLook Density Assessment removes the challenges of subjectivity in breast density reporting, offering accurate and reproducible breast density assessments.
  • This innovative solution analyzes the woman’s breast anatomy and categorizes her breast density within the appropriate BI-RADS® 5th edition density category, automating the process of breast density reporting and empowering clinicians to further personalize breast cancer screening recommendations for patients.

My Density Matters Launches Action Initiative for Earlier Breast Cancer Diagnosis

Retrieved on: 
Thursday, September 15, 2022
VP, NCBC, Collaboration, Awareness, Woman, Mobile, Breast cancer, Check, Health equity, Cancer, Breast, Diagnosis, Collection, Partnership, High-energy-density matter, National Consortium for the Study of Terrorism and Responses to Terrorism, Chief Medical Advisor to the President, Education, Medical imaging, Birth control

HAWTHORN WOODS, Ill., Sept. 15, 2022 /PRNewswire/ -- Awareness is good, but action is essential.

Key Points: 
  • Unfortunately, most people do not know their level of density, and are unaware of "how" to improve their chances of earlier diagnosis.
  • My Density Matters is addressing the "how" for earlier diagnosis with an initiative to move from awareness to education to action.
  • It has inspired her to offer programs through My Density Matters in order to inform women about the implications of breast density.
  • My Density Matters is a 501(c)(3) non-profit with the mission to empower women to find out their breast density, learn their options, and take control of their breast cancer screening.

Malaria breakthrough: A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite

Retrieved on: 
Wednesday, June 8, 2022
Plasmodium falciparum, World Health Organization, World, Death, Assay, MUR, Research, COVID-19, IRBM, Infection, Knowledge, National Consortium for the Study of Terrorism and Responses to Terrorism, Parasitism, List, National Research Council, Canadian university scientific research organizations, Istituto Superiore di Sanità, Malaria, Organization, University, CNR, Ministry of Health and Medical Education, Ministry, ISS, Laboratory, Antibody, Country, Public health, Gametocyte, Efficiency, Nature Communications, Insecticide, Drug discovery, Plasmodium, Peptide, Anopheles, Pharmaceutical industry, Vaccine, Education, Health

This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."

Key Points: 
  • This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."
  • CNR - National Research Council, is a national research public institution with multidisciplinary proficiency, supervised by the Ministry of Education, University and Research (MUR).
  • IRBM is a drug hunting company workingacross all aspects of drug discovery and early development for different modalities small molecule, peptides, and antibodies.
  • IRBM's scientists have discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing.

Malaria breakthrough: A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite

Retrieved on: 
Wednesday, June 8, 2022
Plasmodium falciparum, World Health Organization, World, Death, Assay, MUR, Research, COVID-19, IRBM, Infection, Knowledge, National Consortium for the Study of Terrorism and Responses to Terrorism, Parasitism, List, National Research Council, Canadian university scientific research organizations, Istituto Superiore di Sanità, Malaria, Organization, University, CNR, Ministry of Health and Medical Education, Ministry, ISS, Laboratory, Antibody, Country, Public health, Gametocyte, Efficiency, Nature Communications, Insecticide, Drug discovery, Plasmodium, Peptide, Anopheles, Pharmaceutical industry, Vaccine, Education, Health

This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."

Key Points: 
  • This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."
  • CNR - National Research Council, is a national research public institution with multidisciplinary proficiency, supervised by the Ministry of Education, University and Research (MUR).
  • IRBM is a drug hunting company workingacross all aspects of drug discovery and early development for different modalities small molecule, peptides, and antibodies.
  • IRBM's scientists have discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing.

iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference

Retrieved on: 
Thursday, March 10, 2022
Donald Duck filmography, NASDAQ, University, Private Securities Litigation Reform Act, Physician, Risk, Company, Breast, Tomosynthesis, False, Behavior, Malignancy, U.S. Securities and Exchange Commission, Workflow, Strathcona County, FDA, PST, Conference, Investor, Health, Adoption, MD, Risk assessment, Regulation, Woman, Profound Pharma, GLOBE, News, Disclosure, ICAD, Breast cancer, Patient, Security (finance), Solution, Technology, 3D, Inc., COVID-19, National Consortium for the Study of Terrorism and Responses to Terrorism, Organization, Calcification, Mammography, CEO, Radiology, DBT, Medical imaging, Medicare

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of innovative breast health solutions at the National Consortium of Breast Centers (NCoBC) Annual Conference in Las Vegas, NV from March 11-16 in the iCAD booth (#203).

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of innovative breast health solutions at the National Consortium of Breast Centers (NCoBC) Annual Conference in Las Vegas, NV from March 11-16 in the iCAD booth (#203).
  • iCADs breast health solutions, including ProFound AI for Digital Breast Tomosynthesis (DBT) , or 3D mammography, will also be featured at the first-ever The New Pink Paradigm Summit , taking place on Sunday, March 13.
  • At the event, clinical leadership and advocacy organizations will join forces to improve the standards of breast care and breast cancer survivorship.
  • Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.

Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)

Retrieved on: 
Monday, November 15, 2021
Molecule, MSD, San Raffaele Hospital, Corporation, Safety, Small molecule, Center, Biomarker, ATI, Vinmonopolet, Therapy, TDF, Virology, MD, Collection, Genetics, OSR, HBV, Fortis Healthcare, Organization, Immune system, Doctor of Philosophy, HIV, CAMS, Clevudine, Multimedia, Program, IP, Human, National Consortium for the Study of Terrorism and Responses to Terrorism, Foundation, Research and development, HIV Prevention Trials Network, Degenerative disease, Peptide, Molecular medicine, Antibody, Drug discovery, Hepatitis C, IRBM, Nucleoside, Centre of Excellence on Public Security, Anda, Conditional sentence, Autoimmunity, Patient, CAM, Compound, Pharmaceutical industry

These CAMs enable the selection of a new pipeline candidate, which will be the second molecule in Antios' HBV portfolio.

Key Points: 
  • These CAMs enable the selection of a new pipeline candidate, which will be the second molecule in Antios' HBV portfolio.
  • "Unlike traditional CAMs, which target capsid assembly and disassembly, we believe these molecules may have an additional mechanism of action.
  • ATI-2173, Antios Therapeutics' lead once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate.
  • Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.